ArticleScientific reports2017
Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- MicroMetaSense: Coupling Plasmonic Metasurfaces with Fluorescence for Enhanced Detection of Microplastics in Real Samples.ACS sensors · 2025Article
- Development of a multiplexed lateral flow assay for the serologic detection of HPV-associated head and neck cancer.Cancer biomarkers : section A of Disease markers · 2025Article
- Frontiers of Plant-derived Exosomes from Research Methods to Pharmaceutical Applications in Plant-based Therapeutics.Current drug delivery · 2025Review
- Electrode Modification in Viral Biosensors: A Review.Current medicinal chemistry · 2025Review
- Organoid modeling meets cancers of female reproductive tract.Cell death discovery · 2024Review
- Revolutionizing the female reproductive system research using microfluidic chip platform.Journal of nanobiotechnology · 2023Review
- Aptamer-Based Point-of-Care Devices: Emerging Technologies and Integration of Computational Methods.Biosensors · 2023Review
- Point-of-care diagnosis of cervical cancer: potential protein biomarkers in cervicovaginal fluid.Turkish journal of biology = Turk biyoloji dergisi · 2022Review
- Immunohistochemical Detection of Human Papillomavirus 16 E7 Oncoprotein in Cervical Lesions.Journal of Cancer · 2021Article
- Magneto-Optical Nanostructures for Viral Sensing.Nanomaterials (Basel, Switzerland) · 2020Article
- Emerging Molecular Prospective of SARS-CoV-2: Feasible Nanotechnology Based Detection and Inhibition.Frontiers in microbiology · 2020Review
- Luciferase-Based Detection of Antibodies for the Diagnosis of HPV-Associated Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2019Article
- The Host-Microbe Interplay in Human Papillomavirus-Induced Carcinogenesis.Microorganisms · 2019Review
- Review
- Rapid immunodiagnostics of multiple viral infections in an acoustic microstreaming device with serum and saliva samples.Lab on a chip · 2019Article
- Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women.BMC infectious diseases · 2019Article
- An Automated Microfluidic Assay for Photonic Crystal Enhanced Detection and Analysis of an Antiviral Antibody Cancer Biomarker in Serum.IEEE sensors journal · 2018Article
- Monitoring Neutropenia for Cancer Patients at the Point of Care.Small methods · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.